Osteopontin (OPN) has recently emerged as a key factor in both vascular remodelling and development of atherosclerosis. It has been reported that OPN is regulated by the renin-angiotensin-aldosterone system (RAAS). The aim of this study was to clarify the effect of angiotensin II receptor blockade with valsartan on plasma OPN levels in patients with essential hypertension (EHT). Forty-six patients (mean age, 64 ± 11 years) with EHT were randomly assigned to treatment with amlodipine or valsartan. There were no significant differences in baseline clinical characteristics between the two groups. Blood sampling and blood pressure evaluation were performed before and after 24 weeks of treatment. After 24 weeks, both systolic blood pressure (SBP) and diastolic blood pressure (DBP) were decreased significantly and by the same degree in each treatment group. However, valsartan but not amlodipine decreased plasma OPN levels (baseline and 24-week data-valsartan: 614±224 ng ml
Introduction
Osteopontin (OPN) has been characterized as a highly acidic, phosphoprotein component of bone matrix that is also present in organs such as kidney, brain, pancreas and vasculature. 1 OPN has multiple functions including stimulation of specific cellular events, such as survival, proliferation, and migration in smooth muscle cells, endothelial cells and monocytes/macrophages. [2] [3] [4] [5] OPN is upregulated in a variety of acute and chronic inflammatory conditions, such as wound healing, fibrosis, autoimmune disease and atherosclerosis. 6 The renin-angiotensin-aldosterone system has a significant role in the advent and perpetuation of inflammation both directly and indirectly. OPN is an important cytokine that is regulated by the rennin-angiotensin-aldosterone system. In an in vitro study, Campos et al. 7 reported that OPN mRNA was upregulated by angiotensin II (AII) in rat aortic smooth muscle cells using a DNA microarray method. We have reported that aldosterone also induces OPN mRNA and protein expression in rat renal fibroblasts. 8 In an in vivo study, Bruemmer et al. 9 showed that abdominal aortic aneurysms induced by AII were attenuated in OPN knockout mice.
Clinically, plasma OPN levels have been shown to correlate with future cardiovascular events in patients with chronic stable angina. 10 Even in patients without symptomatic cardiovascular disease, plasma OPN levels correlated with carotid atherosclerosis in patients with essential hypertension. 11 Many experimental studies showed that AII receptor blocker reduced inflammation as well as lowered blood pressure. [12] [13] [14] [15] Clinically, we have reported that valsartan reduced inflammatory cytokines 16 and improved carotid arterial stiffness and haemodynamics, as evaluated by carotid ultrasound. 16, 17 In this study, we determined the effect of two different classes of antihypertensive agents, valsartan and amlodipine, on OPN concentrations in patients with essential hypertension. Furthermore, we attempted to determine the factors that affect changes in OPN levels in patients treated with these antihypertensive agents.
Methods

Study subjects
The ethics committee of the Ehime University Graduate School of Medicine provided approval for the study. Informed consent was obtained from all participating patients. The patients were recruited from the outpatient clinic at Ehime University Hospital. Forty-six patients with essential hypertension without the use of antihypertensive medications were enrolled in this study. Hypertension was defined as a systolic blood pressure (SBP) X140 mm Hg or diastolic blood pressure (DBP) X90 mm Hg. The SBP and DBP were the average of three measurements taken with a brachial sphygmomanometer with the patient in the seated position. Patients with diabetes mellitus, congestive heart failure, previous myocardial infarction, angina pectoris, atrial fibrillation, chronic renal failure (serum creatinine 41.5 mg per 100 ml) or a history of stroke, malignant tumour or autoimmune disease were excluded. Patients were randomized into a group treated with 5 mg kg À1 per day amlodipine (n ¼ 23) or a group treated with 80 mg kg À1 per day valsartan (n ¼ 23). If blood pressure was not controlled after 4 weeks of treatment (SBP4140 mm Hg and/or DBP490 mm Hg), the doses of amlodipine or valsartan were titrated to 10 or 160 mg, respectively. Patients were followed-up at every outpatient clinic visit.
Blood sampling
Blood samples were drawn between 0800 and 1000 hours from the forearm in the supine position after a 20 min rest. Biochemical measurements were performed within 30 min of blood sampling, and blood samples for OPN were centrifuged and stored at À80 1C until assayed by commercially available enzyme-linked immunosorbent assay kits. The serum levels of creatinine, fasting glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol and high-sensitivity C-reactive protein (CRP) were measured on a 200FR analyzer (Toshiba, Tokyo, Japan). Low-density lipoprotein cholesterol levels were calculated using the Friedewald equation. Plasma aldosterone levels were measured by a radioimmunoassay kit (Bio Medical Laboratories, Tokyo, Japan). Plasma OPN levels were measured by an enzyme-linked immunosorbent assay kit (ImmunoBiological Laboratory, Gunma, Japan). All measurements were performed in duplicate. The detection limit and the intra-assay coefficient of variation for the OPN enzyme-linked immunosorbent assay measurements were o5 ng ml À1 . Blood chemistry, OPN, CRP, aldosterone and blood pressure were determined at baseline and after 24 weeks of treatment with each drug.
Statistical analysis
Normally distributed values were expressed as means±standard deviations. If residuals were considered not to be normally distributed, the data were log-transformed. In this study, only CRP was logtransformed. Comparisons between the groups were performed by a Student's t-test or analysis of variance followed by post hoc tests adjusted with a Bonferroni correction factor. Pearson's correlation coefficients were calculated to assess the association between continuous variables. Stepwise regression analysis was performed to clarify the independent determinant of change in OPN. A P-value of o0.05 was considered to be statistically significant.
Results
The clinical characteristics of the study subjects are summarized in Table 1 . None of the participants were taking any medication before this study. Fortysix patients (26 men; mean age, 64±11 years) were included in this study. There were 23 patients in each group, and there were no significant differences in the baseline clinical characteristics between the two groups (Table 1) . No patients were withdrawn from the study for any reason, and there were no serious cardiovascular events during the study.
Patients treated with amlodipine and valsartan had significant decreases of SBP (153 ± 19 to 138±13 mm Hg, P ¼ 0.028; 156±16 to 143±14 mm Hg, P ¼ 0.040, respectively) ( Table 2 ). There were no significant differences in the SBP or DBP reduction between the two treatment groups (reduction in SBP, P ¼ 0.586; reduction in DBP, P ¼ 0.531). Plasma OPN levels were decreased after 24 weeks in patients treated with valsartan (614 ± 224 to 472 ± 268 ng ml À1 , P ¼ 0.006); however, there was no significant change in amlodipine-treated patients (680 ± 151 to 687 ± 234 ng ml À1 , P40.999) (Figure 1 ). In the valsartan group, the reduction in OPN levels (baseline OPN minus 24 weeks OPN) was correlated with the reduction of ln CRP (baseline ln CRP minus 24 weeks ln CRP). In contrast, no correlation was found in the amlodipine group (Table 3, Figure 2 ). Stepwise regression analysis showed that treatment with valsartan and the reduction of ln CRP levels were associated with the reduction of OPN levels (reduction of valsartan: b ¼ 0.332, P ¼ 0.026; reduction of ln CRP: b ¼ 0.366, P ¼ 0.015), and these associations were independent of the reduction of SBP or aldosterone levels (reduction of SBP: b ¼ 0.055, P ¼ 0.700; reduction of aldosterone:
Discussion
In this study, we showed that 24 weeks of treatment with valsartan but not amlodipine decreased plasma OPN levels. The degree of OPN reduction was dependent on the degree of ln CRP reduction.
It is well known that the rennin-angiotensinaldosterone system is a strong stimulator of OPN synthesis. In an in vitro study, Abe et al. 18 reported that OPN expression induced by AII was blocked by valsartan in rat vascular smooth muscle cells. We also reported that aldosterone increased OPN and that the increase was abolished by the mineralocorticoid receptor antagonist, spironolactone, in renal fibroblast. In an in vivo study, Kramer et al. 19 reported that the adriamycin nephropathy induced renal OPN expression and treatment with angiotensin-converting enzyme inhibitor and the combination of angiotensin-converting enzyme inhibitor/ spironolactone reduced renal OPN expression. These previous and present studies indicate that reduction of AII and aldosterone by valsartan may inhibit OPN expression. In transcriptional studies, both AII and aldosterone induced OPN expression through transcriptional factor activator protein 1 that is activated by the pro-inflammatory stimuli. 8 AII receptor blockers decrease OPN both directly and indirectly, through suppression of inflammation, inhibition of macrophage accumulation and reduction of oxidative stress. 20 In this study, the reduction of OPN levels was significantly correlated with the reduction of ln CRP levels only in the valsartan group. In addition, stepwise regression analysis showed that valsartan treatment and the reduction of ln CRP were independent determinants of the reduction of OPN levels. We previously reported that plasma OPN levels were associated with serum CRP levels in hypertensive patients without any prior treatment. 21 Tanaka et al. 22 reported a significant relationship between CRP and OPN in hyper- Angiotensin II blockade reduces plasma osteopontin M Kurata et al cholesterolaemic patients. They showed that the reduction of OPN was correlated with the reduction of CRP, but not with the reduction of low-density lipoprotein cholesterol. These reports indicated a close relationship between the two molecules. We previously reported that valsartan reduced pro-inflammatory cytokines, such as interleukin-6 and tumour necrosis factor-a in hypertensive patients. 16 Blocking AII with valsartan may suppress inflammation and reduce OPN levels. Furthermore, CRP is not only a marker of inflammation, but also a pro-inflammatory molecule itself. 23 This raises the possibility of a direct interaction between CRP and OPN expression. Although we found that valsartan treatment and a reduction of ln CRP levels were independent determinants of a reduction in OPN levels, it is difficult to conclude that an antiinflammatory effect of valsartan is necessary to reduce OPN levels. Kurakawa et al. 24 reported that in a murine model of allergic asthma, increased OPN protein in the broncho-alveolar lavage was inhibited by the corticosteroids, anti-inflammatory drugs. Although their model is completely different in our study subject, anti-inflammatory drugs certainly reduce OPN expression.
In this study, valsartan was effective in reducing plasma OPN levels in hypertensive patients. Although there was no difference in the reduction of blood pressure between the amlodipine and valsartan groups, plasma OPN levels were not changed in the amlodipine group. This result suggests that the reduction of OPN levels by valsartan was independent of its blood pressure lowering effect. There are some clinical trials that showed valsartan was effective in preventing cardiovascular events in hypertensive patients. JIKEI and the Kyoto Heart study showed that the addition of valsartan to conventional treatment prevented more cardiovascular events than supplementary conventional treatment. 25, 26 These beneficial effects cannot be entirely explained by blood pressure control.
A relationship between OPN levels and atherosclerosis has been reported. Many factors that facilitate atherosclerosis, such as hypoxia, high plasma glucose, 27 platelet-derived growth factor, 28 AII, 18,29 aldosterone 8 and mechanical stress, 30 also induce OPN expression. OPN has several effects that may facilitate the development and progression of cardiovascular lesions, including cell adhesion, migration, proliferation, angiogenesis and ectopic mineralization. 31 Reduction of both CRP and OPN levels by AII receptor blockade with valsartan might have beneficial effects on atherosclerosis. We have no data on whether the reduction of OPN levels would prevent future cardiovascular events. However, the JUPITER trial 32 clearly showed that lowering both low-density lipoprotein cholesterol and However, we were not able to determine the precise source of OPN in this study. There were some limitations of our study. First, there were differences in SBP of 5 mm Hg (138 vs 143 mm Hg) and in DBP by 3 mm Hg (84 vs 81 mm Hg) between valsartan and amlodipine treatment, but they did not reach statistical significance. Second, we previously reported that plasma OPN levels were correlated with aldosterone concentrations, 11 but in this study, we were not able to show a relationship between a reduction of aldosterone levels and a reduction of OPN levels. The reason for this result may be the small number of study subjects. Third, we have no data on impaired glucose tolerance in the study participants, because we did not perform a glucose tolerance test. Fourth, we did not include an agematched control group of normotensive subjects. Fifth, the precise mechanisms that control the relationship between CRP and OPN levels remain unknown.
In conclusion, valsartan reduces plasma OPN levels and this effect is independent of its blood pressure lowering effect. Furthermore, lowering CRP is also important in reducing plasma OPN levels. Blocking AII and suppressing inflammation appear to be essential for a reduction in plasma OPN concentrations.
What is known about the topic K Osteopontin (OPN) has been shown to be regulated by the rennin-angiotensin-aldosterone system in experimental studies, and plasma OPN levels reflected the severity of atherosclerosis in clinical studies. K Less is known about how OPN is affected by blocking angiotensin II using angiotensin II receptor blockers (ARBs).
What this study adds K The plasma OPN level was reduced using the ARB, valsartan, but there was no change using the calcium channel blocker, amlodipine, in patients with essential hypertension. K The reduction of OPN levels was correlated with the reduction of C-reactive protein (CRP) levels, and the use of valsartan and a reduction of CRP were independent determinants of the reduction of OPN. K The results suggest that both suppression of angiotensin II and inflammation are needed to reduce plasma OPN levels and further study is needed to determine if a reduction of OPN levels will decrease future cardiovascular events.
Δ OPN (ng ml -1 ) Δ OPN (ng ml -1 )
Δ ln CRP Δ ln CRP Angiotensin II blockade reduces plasma osteopontin M Kurata et al
